Abstract
This study aimed at the preparation and characterization of preformed and in-situ formed liposomes for controlled delivery to the lungs. Two different liposome formulations were prepared and subjected to characterization of physical parameters (vesicle size, appearance, discharge rate, spray pattern and internal pressure) and drug release profile (% cumulative drug release and % drug retained). Formulations were then subjected to accelerated stability studies as per ICH guidelines. It was observed that vesicle size ranged between 2.35 ± 0.23 - 2.41± 0.3 μm and 1.22 ± 0.22- 1.34 ± 0.15 μm respectively for preformed and in-situ formed liposomes. The discharge rate and spray area were in ranges of 110 ± 2.4 -123 ± 2.6 & 115± 2.4 -127±2.3 mg/ actuation & 12.5 ±1.7 -14.1± 2.2 and 13.9 ± 2.1- 14.7± 2.0 cm2 respectively. In-situ liposomes showed better controlled release profile then preformed liposomes as it released 76.5± 2.4 - 58.5 ± 1.8 % drug in 12 hour while retaining 23.5 ± 1.9- 41.5 ± 1.6 % drug whereas preformed liposomes showed cumulative release of 66.5 ± 2.2- 84.5 ± 2.3 % and 15.5 ± 2.4- 33.5± 2.1 % fraction retained. Upon subjection to accelerated conditions for a period of 60 days, preformed liposome completely lost the objective of being controlled release formulation as they showed 92± 2.4 % cumulative release and only 08 ± 1.6 % fraction retained whereas in-situ formulation showed 62 ± 2.3 % cumulative release and 38 ± 2.1 % fraction retained.
Keywords: Tuberculosis, Alveoli, Liposome, Aerosol, Rifampicin, In-situ, Krebs-Henseleit Solution
Current Drug Delivery
Title: In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment
Volume: 6 Issue: 5
Author(s): Praveen Kumar Gaur, Shikha Mishra, V. B. Gupta, M. S. Rathod, Suresh Purohit and Bhavin A. Savla
Affiliation:
Keywords: Tuberculosis, Alveoli, Liposome, Aerosol, Rifampicin, In-situ, Krebs-Henseleit Solution
Abstract: This study aimed at the preparation and characterization of preformed and in-situ formed liposomes for controlled delivery to the lungs. Two different liposome formulations were prepared and subjected to characterization of physical parameters (vesicle size, appearance, discharge rate, spray pattern and internal pressure) and drug release profile (% cumulative drug release and % drug retained). Formulations were then subjected to accelerated stability studies as per ICH guidelines. It was observed that vesicle size ranged between 2.35 ± 0.23 - 2.41± 0.3 μm and 1.22 ± 0.22- 1.34 ± 0.15 μm respectively for preformed and in-situ formed liposomes. The discharge rate and spray area were in ranges of 110 ± 2.4 -123 ± 2.6 & 115± 2.4 -127±2.3 mg/ actuation & 12.5 ±1.7 -14.1± 2.2 and 13.9 ± 2.1- 14.7± 2.0 cm2 respectively. In-situ liposomes showed better controlled release profile then preformed liposomes as it released 76.5± 2.4 - 58.5 ± 1.8 % drug in 12 hour while retaining 23.5 ± 1.9- 41.5 ± 1.6 % drug whereas preformed liposomes showed cumulative release of 66.5 ± 2.2- 84.5 ± 2.3 % and 15.5 ± 2.4- 33.5± 2.1 % fraction retained. Upon subjection to accelerated conditions for a period of 60 days, preformed liposome completely lost the objective of being controlled release formulation as they showed 92± 2.4 % cumulative release and only 08 ± 1.6 % fraction retained whereas in-situ formulation showed 62 ± 2.3 % cumulative release and 38 ± 2.1 % fraction retained.
Export Options
About this article
Cite this article as:
Gaur Kumar Praveen, Mishra Shikha, Gupta B. V., Rathod S. M., Purohit Suresh and Savla A. Bhavin, In-Situ Formation of Liposome of Rifampicin: Better Availability for Better Treatment, Current Drug Delivery 2009; 6 (5) . https://dx.doi.org/10.2174/156720109789941623
DOI https://dx.doi.org/10.2174/156720109789941623 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms and Pathophysiology of Necrotic Cell Death
Current Molecular Medicine Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Impact of Dendritic Cells on Vascular Biology
Current Hypertension Reviews Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm
Current Drug Targets Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Statins And Stroke
Current Medicinal Chemistry Advances in Irrigated Tip Catheter Technology for Treatment of Cardiac Arrhythmias
Recent Patents on Cardiovascular Drug Discovery Phytochemical Characterization of Prickly Pear (Opuntia spp.) and of its Nutritional and Functional Properties: A Review
Current Nutrition & Food Science The Antiplatelet Drug Target in Atherosclerotic Diseases
Cardiovascular & Hematological Disorders-Drug Targets Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Matricellular Proteins in Myocardial Infarction
Current Cardiology Reviews Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets